Effects of ABCG2 421C > A genetic polymorphism on the pharmacokinetics of rivaroxaban in healthy Chinese subjects

The main objective of this study is to investigate whether the CYP3A4/5 and ABC transporter genetic polymorphisms could affect the pharmacokinetics of rivaroxaban in Chinese healthy subjects.2. Forty-two healthy subjects in china were recruited and given a single dose of 2.5 mg rivaroxaban tablets. Plasma concentration of rivaroxaban was determined by UPLC-MS/MS, the CYP3A4 20230 G > A(*1G)), CYP3A5 6986 A > G(*3), ABCB1 1236 C > T, ABCB1 3435 C > T, ABCB1 2677 G > T/A, ABCG2 34 G > A, ABCC2 1249 G > A, ABCC2 3972 C > T, ABCC2 -24 C > T, ABCG2 421 C > A, SLC22A8 715C > T, SLC22A8 445C > A, SLC22A8 779T > G, SLC22A8 829C > T, and SLC22A8 913A > T genotypes were determined by SnapShot Technique.3. In the study, compared with the subjects with C/C of ABCG2 421C > A genotype, individuals with C/A and A/A genotype showed higher the area under the concentration-time curve AUC0-t (289.17 vs 358.56 vs 439.26 ng/h/mL) (p < 0.05 and p < 0.01, respectively), AUC0-∞ (293.92 vs 362.80 vs 442.25 ng/h/mL) (p < 0.05 and p < 0.01, respectively) and the maximum plasma concentration Cmax (56.58 vs 70.36 vs 83.90 ng/mL) (p < 0.05 and p< 0.01, respectively), but lower apparent clearance CL/F (9114.00 vs 7493.82 vs 6017.75 mL/h) (p < 0.05). Following Bonferroni correction, subjects carrying the A/A genotype continued to exhibit statistically significant differences in pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ compared to C/C allele carriers.4. Data in the paper proved that the ABCG2 421C > A polymorphism was significantly related to the pharmacokinetic variability of rivaroxaban.